心可舒治疗冠心病合并焦虑或抑郁:随机对照试验的Meta分析
该系统评价纳入18项随机对照试验共1907例冠心病合并焦虑或抑郁患者,评估心可舒的疗效与安全性。与单用西药相比,心可舒联合西药可显著降低HAMA、SAS、HAMD、SDS评分并提高临床有效率,不良反应轻微。但纳入文献质量普遍偏低,结论需更高质量RCT验证。
要点
- 心可舒联合西药较单用西药显著降低焦虑抑郁量表评分并提高临床有效率。
- 短期不良反应轻微,症状在治疗后消失。
- 证据质量普遍偏低,临床决策需结合患者具体情况并期待更高质量研究。
核心结论
- 当前证据提示心可舒治疗冠心病合并焦虑或抑郁可能有效且安全。
- 因纳入文献质量普遍较低,迫切需要更多高质量、低偏倚风险、足够样本量的随机对照试验验证结论。
研究设计与样本
- 系统检索9个电子数据库,纳入从建库至2022年2月发表的随机对照试验。
- 采用Cochrane手册5.0偏倚风险评估工具和改良Jadad量表评价方法学质量。
- 共纳入18项随机对照试验,涉及1907例受试者,中心可舒组956例,对照组951例。
- 使用RevMan 5.3和Stata 16.0软件进行Meta分析,GRADE Profiler 3.6.1和TSA 0.9.5.10 beta评价证据确定性和结论性。
主要发现
- 与单用西药相比,心可舒联合西药显著降低汉密尔顿抑郁量表评分(MD=-6.74,95%CI -11.58至-1.90,P=0.006)。
关键数值与推荐
- 汉密尔顿抑郁量表评分改善:MD=-6.74,95%CI(-11.58,-1.90),P=0.006。
临床怎么用
- 对于冠心病合并焦虑或抑郁患者,可考虑在常规西药治疗基础上联合心可舒。
- 心可舒作为具有双心效应(psycho-cardiology)的中成药,可能改善焦虑抑郁症状及临床有效率。
- 使用时应关注不良反应,原文报告的不良反应程度轻微且治疗后症状消失。
- 临床决策需结合患者个体情况,并注意现有证据质量偏低的局限性。
局限性
- 纳入文献质量普遍较低,可能影响结论可靠性。
- 仅4项研究详细报告了不良反应。
- 需要更多高质量、低偏倚风险、足够样本量的随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The incidence of coronary heart disease (CHD) complicated with anxiety or depression is increasing year by year. However, many anti-anxiety drugs or antidepressants have a certain degree of adverse reactions and are not easily accepted by patients. Xinkeshu (XKS), as a proprietary Chinese patent medicine with "psycho-cardiology" effect, is one of the commonly used drugs in the treatment of CHD complicated with anxiety or depression in China. AIM OF THE STUDY: To systematically evaluate the efficacy and safety of XKS for CHD complicated with anxiety or depression. METHODS: Nine different electronic databases were independently searched to include randomized controlled trials (RCTs) of XKS for CHD complicated with anxiety or depression published from inception to February 2022, and the methodological quality was evaluated using the bias risk assessment tool from Cochrane Handbook 5.0 and the modified Jadad scale. Meta-analysis was performed using RevMan 5.3 and Stata 16.0 software. The GRADE Profiler 3.6.1 and TSA 0.9.5.10 beta were adopted to evaluate the certainty and conclusiveness of the evidence. RESULTS: A total of 18 RCTs involving 1907 subjects were included. There were 956 subjects in the XKS group and 951 subjects in the control group. Baseline conditions were consistent and comparable between the groups. Compared with single-use western medicine (WM), XKS combined with WM significantly reduced scores of Hamilton Anxiety Scale (HAMA) [Mean difference (MD) = -7.60, 95% confidence interval (95% CI) (-10.37, -4.83), P < 0.000 01], Zung Self-rating Anxiety Scale (SAS) [MD = -10.05, 95% CI (-12.70, -7.41), P < 0.000 01], Hamilton Depression Scale (HAMD) [MD = -6.74, 95% CI (-11.58, -1.90), P = 0.006], and Zung Self-rating Depression Scale (SDS) [MD = -10.75, 95% CI (-17.05,-4.45), P = 0.000 8], as well as improved clinical effective rate [odds ratio (OR) = 4.24, 95% CI (2.47, 7.27), P < 0.000 01]. In terms of safety, 4 studies reported the adverse reactions in detail. The severity was mild and symptoms disappeared after treatment. CONCLUSION: Current evidence indicates that XKS may be effective and safe in the treatment of patients with CHD complicated with anxiety or depression. Since the quality of the literature included in this study was generally low, there is an urgent need for more RCTs with high quality, low bias risk and sufficient sample size to validate our conclusions.
引用
- Liu Q, Wang M, Wang H, et al. Xinkeshu for coronary heart disease complicated with anxiety or depression: A meta-analysis of randomized controlled trials. J Ethnopharmacol. 2023. PMID: 37072088. doi:10.1016/j.jep.2023.116486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。